Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
Commentary

When the Skeleton Is Controlling Pancreatic β-Cell Mass During Development and After

  1. Thomas Bouckenooghe1 and
  2. Bruno Lefebvre2,3⇑
  1. 1Laboratory of Cell Biology, Institute of Life Science, Catholic University of Louvain, Louvain-la-Neuve, Belgium
  2. 2Université Lille Nord de France, Lille, France
  3. 3Alzheimer and Tauopathies, Jean-Pierre Aubert Research Center, INSERM UMR837, Lille, France
  1. Corresponding author: Bruno Lefebvre, bruno.lefebvre{at}inserm.fr.
Diabetes 2014 Mar; 63(3): 838-840. https://doi.org/10.2337/db13-1781
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

The understanding of the phenomenon leading to pancreatic β-cell mass regulation represents a critical step in the development of regenerative therapy for diabetic patients. Type 1 (T1D) and type 2 (T2D) diabetes are characterized by a near-absolute or a relative deficiency of β-cells numbers, respectively. In T1D, at the time of clinical diagnosis, approximately 60–80% of the insulin-producing cells have been destroyed (1). With the currently available treatments, patients with T1D and T2D develop severe long-term complications that clearly reduce their life expectancy (2–4). While insulin replacement continues to be the primary treatment, the need to establish a precise and physiological glucoregulation in order to avoid complications has led to multiple avenues of alternative interventions. Some studies fulfilled this requirement with allogenic transplantation of human islets or insulin-producing cells (5,6). Still under extensive study, the use of pig islets as an alternative source of insulin-producing cells for xenotransplantation seems to be promising and could represent the future of cell therapy for diabetes (7). Other studies have aimed at abrogating the cause of the disease (i.e., the autoimmunity leading to the destruction of β-cells in T1D) (8). Finally, others worked on the reestablishment of an adequate β-cell mass able to restore euglycemia through methods that promote β-cell preservation and/or regeneration in diabetic individuals (9–11).

Pancreatic β-cell mass and function exhibit significant plasticity so that in times of increased insulin demand, such as obesity (12), insulin resistance, and pregnancy (13,14), β-cell numbers and insulin secretory capacity can increase significantly to meet this metabolic demand. During a life span, maintenance of pancreatic β-cell mass is regulated by a complex equilibrium among neogenesis, increase and decrease of cell volume (hypertrophy or atrophy), cell differentiation, and cell proliferation (hyperplasia) and death (apoptosis). Now, there is considerable interest in finding efficient and safe methods to increase β-cell mass by inducing the proliferation of remaining β-cells or favoring the differentiation of resident precursors or progenitors. The proliferation of preexisting β-cells has been shown to be an important source of newly derived adult pancreatic β-cells (15). Under physiological conditions, the rate of primary β-cell replication is very low (in the range of 0–1.2% of the β-cells in adults). Although extensively studied, physiological mechanisms of human β-cell proliferation still remain unknown. Different molecules have been shown to favor β-cell proliferation, mainly prolactin (increasing during pregnancy), serotonin (16), glucagon-like peptide 1 (GLP-1), and betatrophin (17).

In this issue, Wei et al. (18) show that pancreatic β-cell mass is controlled during development and adulthood by osteocalcin via its receptor Gprc6a. Recently, several observations have highlighted that bone, more than supporting tissue, is a real endocrine organ regulating various functions including glucose metabolism and energy expenditure. Osteocalcin, also known as bone γ-carboxyglutamic acid-containing protein, a specific osteoblast-derived hormone, is responsible for these functions (Fig. 1). Osteocalcin can be found in two different forms. In its uncarboxylated form, osteocalcin favors pancreatic β-cell insulin expression and secretion (19) and β-cell proliferation. Several well-documented clinical investigations demonstrated a clear association between glucose metabolism and osteocalcin in humans. Gprc6a is a G-protein–coupled receptor, binding basic and small aliphatic L-α-amino acids and cations, showing a wide tissular expression. More recently, testosterone and osteocalcin have been identified as endogenous Gprc6a agonists. Wei et al. first demonstrated that Gprc6a-specific inactivation in pancreatic β-cells (Gprc6aPdx1−/−) induced glucose intolerance, producing a lower quantity of insulin in response to glucose stimulation but with a normal insulin sensitivity. Compared with their control littermates (Gprc6a fl/fl), no significant differences were observed for body and pancreas weight and glucagon expression.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Osteoblast-secreted osteocalcin in its active (undercarboxylated) form favors insulin sensitivity in muscle, adipose tissue, and liver, having a positive action on glycemia. In the pancreas, active osteocalcin stimulates insulin release and β-cell proliferation. In β-cells, osteocalcin binds to its receptor Gprc6a, inducing the activation of cyclin D1 and cell-cycle progression leading to β-cell proliferation and increase in β-cell mass.

β-Cell proliferation is the main actor of the increasing β-cell mass. In the proliferation process, cyclin and cyclin-dependent kinases play an important role. Previous studies on gene expression analyses of islets or β-cell lines demonstrated that osteocalcin enhances the expression of the insulin genes as well as those encoding proteins implicated in G1/S cell-cycle transition, such as cyclin D1, cyclin D2, and Cdk4. Wei et al. demonstrate that the inactivation of Gprc6a induced a reduction of β-cell proliferation concomitant with a decrease of cyclin D1 gene expression during development and adulthood. Cyclin D2 and Cdk4 expression were not modified. As a consequence, β-cell mass and area were reduced in Gprc6aPdx1−/− mice.

With in vitro and in vivo experiments, Wei et al. showed that in the absence of Gprc6a expression in β-cells osteocalcin has no effects on insulin expression and secretion and β-cell proliferation, clearly showing that Gprc6a is the main, if not the only, osteocalcin receptor acting in β-cells. Moreover, they demonstrate that the reduction of the β-cell mass was only due to a reduction of β-cell proliferation and not to an impaired differentiation. Study of β-cell differentiation markers (Pdx1, Nkx6.1, Nkx2.2, or Isl1) and other endocrine hormones in Gprc6aPdx1−/− mice and their control littermates did not demonstrate any differences.

Interestingly, plasmatic active osteocalcin (undercarboxylated) is detectable early during development and its quantity is constantly increasing to reach a maximum in the postnatal period. During the perinatal period, β-cells undergo a transient peak of proliferation significantly increasing the β-cell mass. This perinatal peak of β-cell proliferation coincides with the enhanced expression of osteocalcin in developing embryos. A recent publication by Mizokami et al. (20) highlighted the effect of osteocalcin via Gprc6a on GLP-1 secretion by the L-cells of the intestine. GLP-1 is known to favor β-cell proliferation and could contribute, to some extent by an indirect way, to the β-cell proliferation observed in the study of Wei et al.

Despite some remaining questions about the complete deciphering of the direct and indirect actions of osteocalcin on β-cell mass, the study by Wei et al. (18) contributes elegantly to bring new important knowledge on the complex and intriguing relation existing between the bones and pancreas. This connection between these two tissues opens new roads for the treatment of diabetes.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 1021.

  • © 2014 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Hirsch IB
    . Insulin analogues. N Engl J Med 2005;352:174–183pmid:15647580
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. The Diabetes Control and Complications Trial Research Group
    . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986pmid:8366922
    OpenUrlCrossRefPubMedWeb of Science
    1. Pambianco G,
    2. Costacou T,
    3. Ellis D,
    4. Becker DJ,
    5. Klein R,
    6. Orchard TJ
    . The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55:1463–1469pmid:16644706
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Reichard P,
    2. Nilsson BY,
    3. Rosenqvist U
    . The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–309pmid:8147960
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A 2013;110:19054–19058
  5. ↵
    Dave SD, Trivedi HL, Chooramani SG, Chandra T. Management of type 1 diabetes mellitus using in vitro autologous adipose tissue trans-differentiated insulin-making cells. BMJ Case Rep 2013;DOI: 10.1136/bcr-2013-200226
  6. ↵
    1. van der Windt DJ,
    2. Bottino R,
    3. Kumar G,
    4. et al
    . Clinical islet xenotransplantation: how close are we? Diabetes 2012;61:3046–3055pmid:23172951
    OpenUrlFREE Full Text
  7. ↵
    1. Keymeulen B,
    2. Vandemeulebroucke E,
    3. Ziegler AG,
    4. et al
    . Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598–2608pmid:15972866
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Ding L,
    2. Gysemans C,
    3. Mathieu C
    . β-Cell differentiation and regeneration in type 1 diabetes. Diabetes Obes Metab 2013;15(Suppl. 3):98–104pmid:24003926
    OpenUrlCrossRefPubMed
    1. Domínguez-Bendala J,
    2. Inverardi L,
    3. Ricordi C
    . Regeneration of pancreatic beta-cell mass for the treatment of diabetes. Expert Opin Biol Ther 2012;12:731–741pmid:22506840
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bouckenooghe T,
    2. Vandewalle B,
    3. Moerman E,
    4. et al
    . Expression of progenitor cell markers during expansion of sorted human pancreatic beta cells. Gene Expr 2005;12:83–98pmid:15892450
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Saisho Y,
    2. Butler AE,
    3. Manesso E,
    4. Elashoff D,
    5. Rizza RA,
    6. Butler PC
    . β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111–117pmid:22875233
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 1997;29:301–307
  12. ↵
    1. Rieck S,
    2. Kaestner KH
    . Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab 2010;21:151–158pmid:20015659
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Dor Y,
    2. Brown J,
    3. Martinez OI,
    4. Melton DA
    . Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004;429:41–46pmid:15129273
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Kim H,
    2. Toyofuku Y,
    3. Lynn FC,
    4. et al
    . Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010;16:804–808pmid:20581837
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Yi P,
    2. Park JS,
    3. Melton DA
    . Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013;153:747–758pmid:23623304
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Wei J,
    2. Hanna T,
    3. Suda N,
    4. Karsenty G,
    5. Ducy P
    . Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a. Diabetes 2014;63:1021–1031pmid:24009262
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008;105:5266–5270
  18. ↵
    1. Mizokami A,
    2. Yasutake Y,
    3. Gao J,
    4. et al
    . Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One 2013;8:e57375pmid:23437377
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Diabetes: 63 (3)

In this Issue

March 2014, 63(3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
When the Skeleton Is Controlling Pancreatic β-Cell Mass During Development and After
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
When the Skeleton Is Controlling Pancreatic β-Cell Mass During Development and After
Thomas Bouckenooghe, Bruno Lefebvre
Diabetes Mar 2014, 63 (3) 838-840; DOI: 10.2337/db13-1781

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

When the Skeleton Is Controlling Pancreatic β-Cell Mass During Development and After
Thomas Bouckenooghe, Bruno Lefebvre
Diabetes Mar 2014, 63 (3) 838-840; DOI: 10.2337/db13-1781
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • “NO” to Autophagy: Fat Does the Trick for Diabetes
  • SCP4: A Small Nuclear Phosphatase Having a Big Effect on FoxOs in Gluconeogenesis
  • Ambient Air Pollution and Type 2 Diabetes: Do the Metabolic Effects of Air Pollution Start Early in Life?
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.